Skip to content
Est. 1998 proudly celebrating our 27th year of championing American business
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

BioRestorative Therapies, Inc.

  • MELVILLE, New York
  • Public · NASDAQ: BRTX
  • 14 employees
$10.3MMarket cap
$359.7KRevenue · FY2025
-$14.2MNet income
14Employees
BRTXNASDAQ
1997IPO

About BioRestorative Therapies, Inc.

BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2025
$359.7K
Net income
-$14.2M
Total assets
$4.1M
Market cap
$10.3M

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: BRTX

15-minute delayed · data by Polygon.io

Market cap
$10.3M
Open
Day range
Prev close
Volume
IPO date
Dec 22, 1997

Market data by Polygon.io · prices are 15-minute delayed

No reviews yet. Be the first to review BioRestorative Therapies, Inc..

Write a review
Explore

Similar companies

Browse all →